Sunesis to Join Panel Discussion at the RBC Capital Markets' Healthcare Conference
24 Febbraio 2011 - 1:30PM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) a biopharmaceutical
company focused on the development and commercialization of new
oncology therapeutics for the treatment of solid and hematologic
cancers, today announced that Daniel Swisher, Chief Executive
Officer of Sunesis, will be participating in a panel discussion
titled "Phase III and Beyond" at the upcoming RBC Capital Markets'
Healthcare Conference on Thursday, March 3, 2011 at 9:00 A.M.
Eastern Time at the New York Palace Hotel.
A live webcast of the panel discussion will be available on the
Sunesis website at http://ir.sunesis.com. A replay of the webcast
will be archived on the "Calendar of Events" page in the Investors
and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the
development and commercialization of new oncology therapeutics for
the treatment of solid and hematologic cancers. Sunesis has built a
highly experienced cancer drug development organization committed
to advancing its lead product candidate, vosaroxin, in multiple
indications to improve the lives of people with cancer. For
additional information on Sunesis, please visit
http://www.sunesis.com.
The Sunesis Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8773
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals,
Inc.
CONTACT: Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals, Inc.
650-266-3717
Grafico Azioni Sunesis Pharmaceuticals, Inc. (MM) (NASDAQ:SNSSD)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Sunesis Pharmaceuticals, Inc. (MM) (NASDAQ:SNSSD)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Sunesis Pharmaceuticals, Inc. (MM) (NASDAQ): 0 articoli recenti
Più Sunesis Pharmaceuticals, Inc. Articoli Notizie